Stockscreener 앱 받기
17.70
1.17%
-0.21
전일 마감가:
$17.91
열려 있는:
$18.02
하루 거래량:
701.15K
Relative Volume:
0.55
시가총액:
$3.03B
수익:
-
순이익/손실:
$-382.71M
주가수익비율:
-6.7557
EPS:
-2.62
순현금흐름:
$-325.64M
1주 성능:
-4.79%
1개월 성능:
+12.03%
6개월 성능:
-24.97%
1년 성능:
-36.72%
1일 변동 폭
$17.48
$18.32
1주일 범위
$17.39
$19.06
52주 변동 폭
$12.72
$34.47
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-580-3099
주소
320 WEST 37TH STREET, NEW YORK, NY
IMVT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
17.70 | 3.18B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
What drives Immunovant Inc. stock priceExceptional profit margins - jammulinksnews.com
Immunovant Inc. Stock Analysis and ForecastUnstoppable trading performance - jammulinksnews.com
Teacher Retirement System of Texas Buys 2,919 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
why immunovant inc. stock attracts strong analyst attentionFree Access to Community - Newser
What analysts say about Immunovant Inc. stockLightning-fast growth - jammulinksnews.com
Is Immunovant Inc. a good long term investmentDynamic profit opportunities - jammulinksnews.com
September 19th Options Now Available For Immunovant (IMVT) - Nasdaq
(IMVT) Trading Advice - news.stocktradersdaily.com
All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy - Yahoo Finance
Goldman Sachs Resumes Coverage of Immunovant (IMVT) with a Hold Rating - MSN
Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High? - Yahoo Finance
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
What makes Immunovant Inc. stock price move sharplyShort Squeeze Radar - Newser
Why Immunovant Inc. stock attracts strong analyst attentionDaily Volume Leaders - Newser
How Immunovant Inc. stock performs during market volatilityFree Trading Strategy Suggestions - Newser
Principal Financial Group Inc. Sells 31,255 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
The Goldman Sachs Group Upgrades Immunovant (NASDAQ:IMVT) to Hold - Defense World
Immunovant (IMVT) chief technology officer Stout sells $26k in stock - Investing.com Australia
Immunovant Executives Sell Shares to Cover Tax Obligations - TradingView
Immunovant Shares Soar 3.60% on Insider Trading Activity - AInvest
Goldman Sachs resumes Immunovant stock coverage with Neutral rating By Investing.com - Investing.com Canada
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by Mirae Asset Global Investments Co. Ltd. - Defense World
(IMVT) Technical Data - news.stocktradersdaily.com
How to Take Advantage of moves in (IMVT) - news.stocktradersdaily.com
Immunovant (NASDAQ:IMVT) Stock Updated Nasdaq Composite - Kalkine Media
Zacks Research Comments on Immunovant FY2028 Earnings - Defense World
Rhumbline Advisers Has $1.43 Million Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
GAMMA Investing LLC Buys 5,229 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Learn to Evaluate (IMVT) using the Charts - news.stocktradersdaily.com
Immunovant, Inc. (NASDAQ:IMVT) Receives $38.33 Consensus Target Price from Brokerages - Defense World
Immunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade) - Seeking Alpha
Cantor Fitzgerald Forecasts Immunovant FY2027 Earnings - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by Wellington Management Group LLP - Defense World
Two Sigma Advisers LP Buys New Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Ameriprise Financial Inc. Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Dexcom (DXCM) and Immunovant (IMVT) - The Globe and Mail
Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Long Term Trading Analysis for (IMVT) - news.stocktradersdaily.com
Leerink Partnrs Estimates Immunovant FY2030 Earnings - Defense World
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus - MSN
Immunovant price target lowered to $35 from $51 at H.C. Wainwright - TipRanks
Immunovant’s Promising Future: Buy Rating Backed by Strategic Advancements and Strong Cash Position - TipRanks
Immunovant Inc reports results for the quarter ended March 31Earnings Summary - TradingView
H.C. Wainwright Adjusts Price Target for Immunovant (IMVT) Amid Future Prospects | IMVT Stock News - GuruFocus
Immunovant Insiders Sell US$5.9m Of Stock, Possibly Signalling Caution - simplywall.st
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):